Renaissance Technologies LLC Raises Stock Holdings in Embecta Corp. $EMBC

Renaissance Technologies LLC boosted its stake in shares of Embecta Corp. (NASDAQ:EMBC) by 299.7% during the first quarter, Holdings Channel.com reports. The firm owned 144,287 shares of the company’s stock after purchasing an additional 108,185 shares during the quarter. Renaissance Technologies LLC’s holdings in Embecta were worth $1,275,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Royal Bank of Canada raised its holdings in Embecta by 38.3% in the first quarter. Royal Bank of Canada now owns 18,201 shares of the company’s stock worth $232,000 after purchasing an additional 5,036 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Embecta by 3.7% in the 1st quarter. AQR Capital Management LLC now owns 225,641 shares of the company’s stock valued at $2,738,000 after buying an additional 8,109 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Embecta by 2.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after buying an additional 1,159 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Embecta by 4.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company’s stock worth $2,195,000 after buying an additional 7,894 shares during the last quarter. Finally, Jane Street Group LLC raised its stake in shares of Embecta by 224.0% during the 1st quarter. Jane Street Group LLC now owns 132,688 shares of the company’s stock worth $1,692,000 after acquiring an additional 91,729 shares in the last quarter. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Insider Buying and Selling at Embecta

In related news, CEO Devdatt Kurdikar acquired 30,000 shares of the stock in a transaction on Wednesday, August 12th. The shares were acquired at an average price of $4.70 per share, for a total transaction of $141,000.00. Following the transaction, the chief executive officer owned 804,919 shares in the company, valued at approximately $3,783,119.30. This trade represents a 3.87% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jacob Elguicze acquired 20,000 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were purchased at an average cost of $4.67 per share, for a total transaction of $93,400.00. Following the purchase, the chief financial officer directly owned 309,139 shares in the company, valued at approximately $1,443,679.13. This trade represents a 6.92% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 70,000 shares of company stock valued at $334,200. 1.30% of the stock is owned by company insiders.

Embecta Price Performance

EMBC stock opened at $5.11 on Friday. The firm’s fifty day simple moving average is $3.46 and its 200-day simple moving average is $6.42. The company has a market capitalization of $289.53 million, a P/E ratio of 3.45 and a beta of 0.81. Embecta Corp. has a 12 month low of $2.77 and a 12 month high of $15.55.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.29. The business had revenue of $271.70 million during the quarter, compared to analyst estimates of $254.53 million. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%.The company’s revenue was down 8.1% on a year-over-year basis. During the same quarter last year, the business posted $1.12 EPS. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. As a group, sell-side analysts forecast that Embecta Corp. will post 1.84 earnings per share for the current year.

Embecta Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th will be issued a $0.01 dividend. The ex-dividend date of this dividend is Thursday, August 27th. This represents a $0.04 dividend on an annualized basis and a yield of 0.8%. Embecta’s payout ratio is presently 2.70%.

Embecta News Roundup

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: CEO Devdatt Kurdikar purchased 30,000 shares for approximately $141,000, while CFO Jacob Elguicze bought 20,000 shares for about $93,400. Director Jeffrey Z. Mann also acquired 20,000 shares for roughly $99,800. The coordinated purchases—made near recent lows and disclosed in SEC filings—may signal that senior leaders view the stock as undervalued or believe the company’s long-term outlook is stronger than its recent performance suggests. Embecta CEO insider purchase filing
• Neutral Sentiment: Multiple law firms publicized the same pending securities class action and the August 17 lead-plaintiff deadline for investors who purchased Embecta shares between November 25, 2025, and May 4, 2026. The announcements largely seek participation and do not represent new findings or a court judgment against Embecta. Rosen Embecta class action deadline notice
• Negative Sentiment: The litigation alleges that Embecta misrepresented the commercial stability of its insulin pen-needle business and that its CEO and CFO issued misleading fiscal 2026 guidance. Plaintiffs claim the disclosures contributed to a sharp stock decline, potentially exposing Embecta and certain executives to financial liability, legal expenses, and reputational damage. These are allegations, and their ultimate merits remain unresolved. Hagens Berman Embecta lawsuit investigation

Analyst Ratings Changes

EMBC has been the subject of a number of analyst reports. Zacks Research raised shares of Embecta from a “strong sell” rating to a “hold” rating in a research report on Friday, July 17th. Wall Street Zen lowered shares of Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Bank of America reduced their price target on Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a research report on Monday, May 18th. Mizuho decreased their price objective on Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Finally, BTIG Research cut Embecta from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 5th. Three equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $11.00.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.